Methionine restriction inhibits pancreatic cancer proliferation while suppressing JAK2/STAT3 pathway.

Background: Methionine restriction (MR) has been demonstrated to exhibit anti-tumor effects in various types of cancer, including pancreatic cancer (PC). However, the detailed mechanism induced by MR remains still unclear. This study aims to reveal the underlying mechanism of MR on PC by proteomic analysis.

Massive bleeding and perforation due to post-colectomy pan-enteritis with a significant response to biologic in a patient with ulcerative colitis: a case report.

Background: Post-colectomy pan-enteritis in ulcerative colitis (UC) is very rare, but it is often severe and fatal. We present a case of massive bleeding and perforation due to post-colectomy pan-enteritis, which showed a significant response to biologics in a UC patient.

Case Presentation: A 30-year-old woman with a 5-month history of pancolitis UC underwent subtotal colectomy with ileostomy and mucosal fistula for refractory UC.

Diagnostic errors in uncommon conditions: a systematic review of case reports of diagnostic errors.

Objectives: To assess the usefulness of case reports as sources for research on diagnostic errors in uncommon diseases and atypical presentations.

Content: We reviewed 563 case reports of diagnostic error. The commonality of the final diagnoses was classified based on the description in the articles, Orphanet, or epidemiological data on available references; the typicality of presentation was classified based on the description in the articles and the judgment of the physician researchers.

[Seven Cases of Metastatic Colorectal Cancer Treated with Dose-Reduced and Duration-Reduced Regorafenib Treatment].

Regorafenib is widely used for patients with metastatic colorectal cancer, following disease progression with standard therapies.However, regorafenib has severe toxicities; therefore, careful monitoring and treatment are necessary.Several studies have investigated the efficacy of initial dose reductions.

Biotin enhances glucose-stimulated insulin secretion in the isolated perfused pancreas of the rat.

The effects of biotin on insulin secretion in pair-fed control rats and biotin-deficient rats were investigated using the method of isolated pancreas perfusion. Isolated pancreas perfusion was performed using 20 mM glucose, 10 mM arginine, and 20 mM glucose plus various concentrations of biotin (20 mM glucose + biotin solution) as stimulants of insulin secretion. The insulin response to 20 mM glucose in biotin-deficient rats was approximately 22% of that seen in control rats.

A high biotin diet improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus.

The Otsuka Long-Evans Tokushima Fatty (OLETF) rat, serving as a spontaneously diabetic model with non-insulin-dependent diabetes mellitus (NIDDM), exhibits impaired glucose tolerance (IGT) at about 16 weeks of age. In this study, we investigated whether or not biotin, a water-soluble vitamin, improved the IGT of OLETF rats. To this end, we administered diets containing one of three levels of biotin, a high-biotin diet (BH), a normal-biotin diet (BN) and a basal-biotin diet (BB), to OLETF rats up to 24 weeks of age.

Biochemical consequences of biotin deficiency in osteogenic disorder shionogi rats.

The biological consequences of biotin deficiency in rats were investigated using osteogenic disorder Shionogi rats which have a hereditary defect in ascorbic acid synthesizing ability. Decrease of liver ascorbic acid content and fasting plasma glucose and an increase of plasma non-esterified fatty acid (NEFA) appeared in biotin deficient rats fed a diet containing 200 mg ascorbic acid per 100 g diet, compared with the pair fed control. On the other hand, in the case of rats fed a diet containing 500 mg ascorbic acid, although the clinical features of biotin deficiency developed, the ascorbic acid contents of liver and adrenal gland increased in comparison with those of AsA 200 mg groups, and the alterations of plasma levels of glucose and NEFA were improved partially in glucose and greatly in NEFA, respectively.

Effect of pindolol, a beta-adrenoceptor blocking agent, on lipid metabolism.

Pindolol, a beta-adrenoceptor blocking agent, was administered to rats to determine the effects of the drug on lipid and lipoprotein in plasma and tissues. The drug caused significant reductions in plasma triglyceride, free fatty acid and very low density lipoprotein. As for lipoprotein lipase activity, the drug produced varying effects; an increase in the heart and a reduction in the adipose tissue.

Formation of a vasopressor substance in the incubated serum of patients with various hypertensive diseases.

A vasoactive substance was produced in serum when incubated at 37 degrees C. This substance differed from other known vasoactive agents. It was a phospholipid and caused an elevation in blood pressure by its direct vasoconstriction.

Carnitine depletion as a probable cause of hyperlipidemia in uremic patients on maintenance hemodialysis.

The mechanism of te development of hemodialysis hyperlipidemia was investigated in uremic patients on maintenance hemodialysis. Hemodialysis treatment lost large amounts of carnitine from blood into the dialysate fluid, resulting in the reduction in serum concentration of carnitine. After the treatments were repeated for more than 12 months, the serum concentration of carnitine reduced markedly and the serum triglyceride level increased significantly.

Effect of aging on lipid and carnitine metabolism.

In healthy subjects aged 20 to 50 years, the urinary excretion of carnitine and its serum concentration increased rapidly and markedly after synthetic beta 1-24 ACTH-Z was injected. Their serum triglyceride levels changed inversely. In contrast, healthy subjects older than 70 and patients aged 45 to 50 with atherosclerosis exhibited lower and delayed changes of carnitine excretion and serum concentrations of carnitine and lipid after ACTH injection.

Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia.

Serum-lipid concentrations were determined in patients with type-IV hyperlipoproteinaemia treated with 900 mg/day oral DL-carnitine chloride. Serum-triglyceride was significantly reduced and concentrations continued to decline as carnitine administration continued. Total and esterified cholesterol concentrations did not change.

Urinary excretion of carnitine in patients with hyperthyroidism and hypothyroidism: augmentation by thyroid hormone.

Urinary excretion of carnitine and serum concentrations of carnitine, triglyceride, and free fatty acids were measured in 54 hyperthyroid and 13 hypothyroid patients, and the results were compared with those of normal subjects. In hyperthyroid patients urinary excretion of carnitine was highly increased above that of the control subjects. On adequate treatment with antithyroid drug, carnitine excretion was reduced to the normal range, and serum lipids changed in parallel.

Urinary excretion of carnitine in man.

A convenient assay procedure for urinary carnitine is described. Urinary excretion of carnitine is determined in human subjects in various experimental states. Average excretions by this procedure were 59.

Separation and determination of carnitine and its esters in human serum.

A colorimetric method for the determination of carnitine and its derivatives is described. Free carnitine, acetylcarnitine and palmitoylcarnitine were extracted with chloroform-methanol. After evaporation, the residue was dissolved in n-butanol and water; palmitoylcarnitine in the organic phase, and free carnitine and acetylcarnitine by passing the aqueous phase through a column of Amberlite CG-120 (H+).